Federal response to vital Medicine shortages in US hospitals

A New York Times article (Oct 31, 2011) describes Federal attempts to ease shoratges of sterile injectables that constutue 74 % of drug shortages.  The government blames market concentration – 90 % of the medicines are bought by five hospital purchasing groups, and one global company supplies 90 % of the supply in many cases.   prices have increased eighty fold in some cases – a leukemia drug price went up from $ 12 to $ 990 per vial.  Will the proposed solution to increase the number of inspectors, by charging a fee to generic companies, resolve the shortage problem ? Would making it the legal responsibility of manufacturers to aniticpate shortages resolve the problem ? Or should the federal government intervene more directly by stockiling or manufacturing the drugs ?

Unknown's avatar

About aviyer2010

Dean and H. William Lichtenberger Chair in Management at the School of Management, University at Buffalo, State University of New York.
This entry was posted in Global Contexts, Operations Management, Supply Chain Issues and tagged , , , , , , , , . Bookmark the permalink.

Leave a comment